Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S326000, C514S327000, C514S330000
Reexamination Certificate
active
07932267
ABSTRACT:
The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.
REFERENCES:
patent: 7256005 (2007-08-01), Zitzmann et al.
patent: 7638488 (2009-12-01), Blatt et al.
patent: 2004/0110795 (2004-06-01), Zitzmann et al.
patent: 2005/0119310 (2005-06-01), Mueller et al.
patent: 2005/0256168 (2005-11-01), Block et al.
[R] Fischer et al., “Treatment for Hepatitis C Virus and Cannabis Use in Illicit Drug User Patients: Implications and Questions,” European Journal of Gastroenterology & Heptatology, 18(10), 1039-1042 (Oct. 2006).
(S) Sylvestre et al., “Cannabis Use Improves Retention and Virological Outcomes in Patients Treated for Hepatitis C,” European Journal of Gastroenterology & Heptatology, 18(10), 1057-1063 (Oct. 2006); only abstract supplied.
(T) O'Neil et al. (eds.), The Merck Index, 13th Edition, Merck & Co., Inc., Whitehouse Station, NJ, 2001, only pages 5, 321 and 1103-1104 supplied: see in particular entries 18, 1906 & 6210.
(U) Karpas et al., “Aminosugar Derivatives as Potential Anti-Human Immunodeficiency Virus Agents,” Proc. National Academy of Sciences USA, 85 , 9229-9233 (Dec. 1988).
(V) Chitturi et al., “Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-inflammatory Drugs, Anti-hypertensives, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs,” Semin. Liver Disease, 22(2), 169-183 (2002); only abstract supplied.
(W) Andersson et al., “Inhibition of Glycogen Breakdown by Imino Sugars in vitro and in vivo,” Biochemical Pharmacology, 67(4), 697-705 (Feb. 15, 2004).
(X) Block, T., Virological Basis of the Broad Antiviral Activity of the Iminosugar Families Called “Glucovirs” and “Alkovirs,” Abstracts of Papers, 230th ACS National Meeting, American Chemical Society, Washington, DC, Aug. 28-Sep. 1, 2005, Abstract No. CARB-041.
(Y) Buckvold et al., “Bovine Viral Diarrhea as a Surrogate Model of Heptatiis C Virus for the Evaluation of Antiviral Agents,” Antiviral Research, 60(1), 1-15 (Sep. 2003); PubMed I.D.: 14516916; only PubMed abstract supplied by applicant.
Blatt Lawrence M.
Seiwert Scott
Tan Hua
Crane Lawrence E
Intermune, Inc.
Marshall & Gerstein & Borun LLP
LandOfFree
Use of α-glucosidase inhibitors to treat alphavirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of α-glucosidase inhibitors to treat alphavirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of α-glucosidase inhibitors to treat alphavirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670218